Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case
E. I. Alekseeva,
S. I. Valieva,
T. M. Bzarova,
R. V. Denisova,
T. V. Sleptsova,
O. L. Lomakina,
A. M. Chomakhidze https://doi.org/10.15690/pf.v13i4.1613
Abstract
This article describes a case of successfully used tocilizumab (interleukin 6 receptors monoclonal antibodies) in a two-year patient with severe systemic juvenile idiopathic arthritis resistant to oral and parenteral glucocorticoids, nonsteroidal anti-inflammatory drugs, and methotrexate. Just after the first injection of tocilizumab, fever and pain ceased, morning stiffness decreased significantly; laboratory disease activity indices normalized by the 4th week of drug use; by the 16th week inflammatory changes in the joints regressed completely, the disease entered its inactive phase. After using tocilizumab, remission duration was 20 months for articular syndrome and systemic manifestations. No adverse reactions have been registered.
About the Authors
E. I. Alekseeva
Scientific Center of Children’s Health;
Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
S. I. Valieva
Scientific Center of Children’s Health;
Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
T. M. Bzarova
Scientific Center of Children’s Health;
Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
R. V. Denisova
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
T. V. Sleptsova
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
O. L. Lomakina
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
A. M. Chomakhidze
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Company; 2001. p. 218–322.
2. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
3. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491–496.
4. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Под общей ред. А.А. Баранова. — М.: Веди; 2007. — 368 с. [Alexeeva EI, Litvitskii PF. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by A.A. Baranov. Moscow: VEDI; 2007. 368 p. (In Russ).]
5. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–1857. doi: 10.1002/1529-0131(200008)43: 8<1849::aid-anr22>3.0.co;2-f.
6. Алексеева Е.И., Валиева С.И., Бзарова Т.М., Денисова Р.В. Метотрексат — «золотой стандарт» лечения ювенильного ревматоидного артрита // Вопросы современной педиатрии. — 2011. — Т. 10.— № 1. — С. 42–49. [Alexeeva EI, Valieva SI, Bzarova TM, Denisova RV. Methotrexate — «gold standard» of juvenile rheumatoid arthritis treatment. Current pediatrics. 2011;10(1):42–49. (In Russ).]
7. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin-6 mediated disease? J Rheumatol. 1998; 25(2):203–207.
8. Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72(4):583–589. doi: 10.1136/annrheumdis-2012-202470.
9. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7(6):R1281–1288. doi: 10.1186/ar1826.
10. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. doi: 10.1016/S0140-6736(08)60454-7.
11. Sawhney S, Aggarwal M. Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India. Pediatr Rheumatol Online J. 2012;10(Suppl 1):A49. doi: 10.1186/1546-0096-10-S1-A49.
12. De Benedetti F, Brunner HI, Allen R, et al. Tocilizumab is efficacious in patients with systemic juvenile idiopathic arthritis across baseline demographic and disease characteristics and prior/baseline treatments: 52-week data from a phase 3 clinical trial. Arthritis Rheum. 2011;63(Suppl):1029–1030.
13. Yokota S, Imagawa T, Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009;68(Suppl 3):715.
14. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395. doi: 10.1056/NEJMoa1112802.
15. Ювенильный артрит: клинические рекомендации для педиатров. Детская ревматология / Под ред. А.А. Баранова, Е.И. Алексеевой. — М.: ПедиатрЪ; 2013.— 120 с. [Yuvenil'nyi artrit: klinicheskie rekomendatsii dlya pediatrov. Detskaya revmatologiya. Ed by A.A. Baranov, E.I. Alexeeva. Scientific Center of children’s Health of RAMS, I.M. Sechenov First Moscow Medical University. Moscow: Pediatr; 2013. 120 p. (In Russ).]
16. Баранов А.А., Алексеева И.И., Денисова Р.В. и др. Ретроспективный анализ эффективности и безопасности тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритом: 12 месяцев наблюдения // Вопросы современной педиатрии. — 2013. — Т. 12.— № 2. — С. 26–34. [Baranov AA, Alekseeva II, Denisova RV, et al. Retrospective analysis of efficacy and safety of Tocilizumab treatment in children with severe systemic juvenile idiopathic arthritis: 12-month follow-up. Current pediatrics. 2013;12(2):26–34. (In Russ).] doi:10.15690/vsp.v12i2.617.
17. Каледа М.И., Никишина И.П. Тоцилизумаб в лечении детей с системным вариантом ювенильного артрита: анализ факторов, влияющих на эффективность терапии в долгосрочном периоде // Вопросы современной педиатрии. — 2015. — Т. 14.— № 2. — С. 236–245. [Kaleda MI, Nikishina IP. Tocilizumab in the treatment of children with systemic juvenile arthritis: analysis of factors influencing the therapy efficiency in the long term. Current pediatrics. 2015;14(2):236–245. (In Russ).] doi:10.15690/vsp.v14i2.1292.
Review
For citations:
Alekseeva E.I., Valieva S.I., Bzarova T.M., Denisova R.V., Sleptsova T.V., Lomakina O.L., Chomakhidze A.M. Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case. Pediatric pharmacology. 2016;13(4):390-394. (In Russ.) https://doi.org/10.15690/pf.v13i4.1613
Views:
734
Email this article 